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was for prescription medications, at $747,551,471 (mean
= $59.87; 95% CL = $51.95–$67.78). Ofﬁce-based
medical provider visits were $396,946,065 (mean =
$73.50; 95% CL = $60.20–$86.80). Emergency depart-
ment visits were approximately $110 million while out-
patient services, inpatient stays, and home health services
were each below $100 million. CONCLUSIONS: The
cost of treating a migraineur was estimated to be $293 in
1999, nearly 3 times higher than $100 reported in 1994.
However, total direct costs in 1999 were $1.5 billion,
only 50% higher than $1 billion reported in 1994. 
Prescription expenditures at greater than 50% of direct
costs were a major factor in the increase in incident cost.
The rate of increase in total costs was less than the rate
of increase in incident costs, suggesting either greater drug
efﬁcacy or reduced use of more costly medical care 
alternatives.
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OBJECTIVES: There is a wide array of pharmacological
agents available for the acute treatment of migraine
headache. The 5-HT1B/1D receptor agonists (triptans),
ergotamine derivatives, and isometheptene/dichlo-
ralphenazone combination products represent the most
frequently prescribed migraine-speciﬁc therapies. Our
objective is to describe the costs and explore the 
utilization patterns of migraine-speciﬁc therapies in the
Wisconsin Medicaid population. METHODS: Wisconsin
Medicaid drug utilization data for 2001 was used. These
data were obtained directly from the Centers for
Medicare & Medicaid Services website. National Drug
Codes were used to extract quarterly utilization data for
products belonging to three classes of acute migraine ther-
apies (triptans, ergotamine derivatives, and isomethep-
tene/dichloralphenazone combination products). Analysis
of utilization was performed for each quarter of 2001 by
aggregating the amount and number of claims reimbursed
across products. Further analysis was conducted to
examine the average cost per claim between pharma-
cological classes and individual triptan therapies.
RESULTS: In 2001, the Wisconsin Medicaid program
reimbursed acute-migraine drug treatment claims totaling
$2,372,463.66, representing 15,120 prescription claims.
Most of this expenditure (98.3%/$2,331,090.71) was 
a result of triptan claims, with 1.5 % ($34,715.25) and
0.2% ($6,657.70) representing ergotamine derivative and
isometheptene/dichloralphenazone combination product
claims, respectively. Within the triptan class, sumitriptan
(9,122/$1,599,212.19), rizatriptan (2,388/$306,947.59)
and zolmatriptan (1,877/$264,947.76) composed the
ﬁrst, second, and third most utilized products. Cost per
claim values within the oral triptans varied greatly 
with a high of $180.72 (sumitriptan) and a low of $81.51
(almotriptan). CONCLUSION: In the Wisconsin Medic-
aid population, utilization of migraine-speciﬁc therapies
was weighted heavily towards the triptans. With the large
variation in claims cost among oral triptans, consider-
able cost savings could be realized if a system was 
implemented to increase utilization of newer, second-
generation triptans (non-sumatriptan) as ﬁrst-line
therapy. However, such a clinical decision should be sup-
ported by comparative clinical trail data that supports
equivalent or superior efﬁcacy to sumatriptan.
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OBJECTIVE: Clinical recommendations advocate use of
carbamazepine, lamotrigine, and gabapentin rather than
phenobarbital and phenytoin for treating older patients
with epilepsy. We describe prescribing patterns for 
older veterans newly diagnosed with epilepsy, determine
if practice is consistent with clinical recommendations,
and describe those at greatest risk of receiving these
potentially inappropriate antiepileptic drugs (AEDs).
METHODS: Retrospective national inpatient, outpatient,
and pharmacy data from the Veterans Health Adminis-
tration (VA), were used to identify veterans >64 years
with an epilepsy diagnosis during ﬁscal year 1999 (FY99)
who also received AEDs from the VA in FY99. Patients
who were seen in the VA during FY97-98 with no 
previous diagnosis of epilepsy were selected. We identi-
ﬁed patients’ AED regimen for FY99, demographic char-
acteristics, neurology consultations, and disease severity.
We used logistic regression to identify patients most likely
to receive phenobarbital and phenytoin. RESULTS:
Eighty-ﬁve percent received monotherapy. Ten percent 
of patients received regimens containing phenobarbital,
68% received regimens including phenytoin, and 25%
received only recommended AEDs. Logistic regression
analyses indicated that patients with more severe disease
were less likely to receive phenobarbital monotherapy
than other monotherapy (OR: 0.47, 95% CI 0.22–0.98)
and phenobarbital combinations than other combina-
tions (OR: 0.29, 95% CI 0.13–0.70). Patients receiving
neurology consultation were less likely to receive pheny-
toin monotherapy than monotherapies consistent with
clinical recommendations (New OR: 0.49, 95% CI
0.39–0.61). CONCLUSIONS: A surprising number of
newly diagnosed veterans received phenobarbital despite
its well known adverse effects. Moreover, our ﬁnding 
that nearly 70% receive phenytoin is not consistent with
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recent recommendations for epilepsy care in the elderly.
Research is needed to identify why new patients receive
phenobarbital. The vast use of phenytoin suggests
research evaluating the impact of phenytoin and other
AEDs on the elderly in actual practice may be needed to
facilitate adoption of recent clinical recommendations.
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OBJECTIVES: Allergies and many sedating over-the-
counter (OTC) allergy medications have been shown to
have a signiﬁcant and negative impact on lost productive
time at work. We examine the impact of an allergy
program designed to reduce sedating allergy medication
use and its impact on employee-reported lost productiv-
ity within a large southern California medical group.
METHODS: A baseline questionnaire designed to
measure allergy symptoms, severity, treatment strategies,
and disease burden was distributed to 712 employees in
November 2001 with a follow-up questionnaire sent in
November 2002. We calculated change in self-reported
productive time lost due to allergy related full and partial
missed days, and presenteeism (lower productive time
while at work) from merged baseline and follow-up data.
Interventions included recommended treatment guide-
lines that were developed and distributed to all physicians
and clinics. Employees were encouraged to discuss their
allergy medications and treatment strategies with their
physicians and were provided access to a corporate
Intranet site for additional allergy-speciﬁc information.
RESULTS: Response rates of 85% and 58% were
achieved at baseline and 1-year follow-up. In addition,
59% of allergic employees participated in the program
with 44% reporting visiting a doctor and 28% using the
Intranet. Sedating OTC medication use dropped from
38% to 21% (p < .0001). Allergy speciﬁc average
monthly hours missed decreased due to presenteeism (7.2
hours; p < .0001) and overall (5.5 hours; p = .0076) per
allergic employee. Average monthly hours missed
increased due to full days (1.1 hour) and partial days (.06
hour) but were not statistically signiﬁcant. CONCLU-
SIONS: While allergies account for a signiﬁcant number
of lost productive work hours, an allergy program can
successfully reduce sedating medication use, consequent
disease burden, and lost productive work time. Projected
annually, appropriate treatment of allergy symptoms
resulted in cost savings of approximately $1254 per aller-
gic employee.
EP2
COST ANALYSIS OF HEPATITIS C VIRUS (HCV)
INFECTION:AN EMPLOYER’S PERSPECTIVE
Duh MS1, Moyneur É2,Van Audenrode M3, Mody SH4,
Piech CT4
1Analysis Group/Economics, Boston, MA, USA; 2Analysis
Group/Economics, Montreal, QC, Canada; 3Université Laval,
Québec, QC, Canada; 4Ortho Biotech Products, LP,
Bridgewater, NJ, USA
OBJECTIVE: With improvements in therapy, HCV
disease progression can be better controlled and a greater
number of infected patients are able to remain in the
workforce. This analysis quantiﬁes the incremental direct
(medical, drugs) and indirect (absenteeism, disability)
costs of HCV from an employer’s perspective.
METHODS: Based on eligibility, medical, pharmacy and
disability claims data from seven major US employers
covering January 1, 1998 through June 30, 2001, we
identiﬁed 833 HCV infected patients having at least 2
claims with a HCV ICD-9 diagnosis code less than 90
days apart, ribavirin and interferon combination therapy,
a conﬁrmatory HCV lab test followed by a HCV diag-
nosis, or a HCV diagnosis coupled with non-alcoholic 
cirrhosis, hepatocarcinoma, liver transplantation, or
cryoglobulinemia. A 10% random sample of 148,166
uninfected individuals was chosen as controls. Employer
costs resulted from direct medical costs and employee
productivity loss. A tobit regression, which corrects for
non-normality of costs, included controls for age, gender,
health plan, location, alcohol abuse, HIV status, and
illicit drug use. RESULTS: The unadjusted ratio of mean
direct costs for HCV infected patients compared to unin-
fected patients was 7.9 :1 ($857.4 vs. $108.1 per patient-
month, p < .01). The ratio for indirect costs was 4.0 :1
($88.7 vs. $22.3 per patient-month, p < .01). After con-
trolling for confounding factors, the ratios were 5.6 :1
(95% CI: 5.6–5.7) for direct costs, and 8.1:1 (95% CI:
7.9–8.4) for indirect costs. Regressions on sub-categories
yielded costs ratios for inpatient care, outpatient care,
prescription drugs, absenteeism, and disability (short 
and long-term) of 5.3 :1 (95% CI: 5.2–5.4), 5.0:1 (95%
CI: 5.0–5.1), 7.5:1 (95% CI: 7.4–7.5), 5.5:1 (95% 
CI: 5.4–5.7), and 10.0 :1 (95% CI: 9.2–10.8), respec-
tively. CONCLUSION: Both the unadjusted and adjusted
cost ratios for HCV infected patients compared to unin-
fected patients indicate that infection results in statisti-
cally signiﬁcant increases in both direct and indirect costs
to the employers.
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